190 related articles for article (PubMed ID: 20523121)
1. Development of a Chlamydia trachomatis T cell Vaccine.
Karunakaran KP; Yu H; Foster LJ; Brunham RC
Hum Vaccin; 2010 Aug; 6(8):676-80. PubMed ID: 20523121
[TBL] [Abstract][Full Text] [Related]
2. Using MHC Molecules to Define a Chlamydia T Cell Vaccine.
Karunakaran KP; Yu H; Foster LJ; Brunham RC
Methods Mol Biol; 2016; 1403():419-32. PubMed ID: 27076145
[TBL] [Abstract][Full Text] [Related]
3. Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines.
Finco O; Frigimelica E; Buricchi F; Petracca R; Galli G; Faenzi E; Meoni E; Bonci A; Agnusdei M; Nardelli F; Bartolini E; Scarselli M; Caproni E; Laera D; Zedda L; Skibinski D; Giovinazzi S; Bastone R; Ianni E; Cevenini R; Grandi G; Grifantini R
Proc Natl Acad Sci U S A; 2011 Jun; 108(24):9969-74. PubMed ID: 21628568
[TBL] [Abstract][Full Text] [Related]
4. High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge.
Picard MD; Cohane KP; Gierahn TM; Higgins DE; Flechtner JB
Vaccine; 2012 Jun; 30(29):4387-93. PubMed ID: 22682294
[TBL] [Abstract][Full Text] [Related]
5. Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice.
Yu H; Karunakaran KP; Jiang X; Shen C; Andersen P; Brunham RC
Infect Immun; 2012 Apr; 80(4):1510-8. PubMed ID: 22290151
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis.
Coler RN; Bhatia A; Maisonneuve JF; Probst P; Barth B; Ovendale P; Fang H; Alderson M; Lobet Y; Cohen J; Mettens P; Reed SG
FEMS Immunol Med Microbiol; 2009 Mar; 55(2):258-70. PubMed ID: 19281568
[TBL] [Abstract][Full Text] [Related]
7. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.
Yu H; Jiang X; Shen C; Karunakaran KP; Jiang J; Rosin NL; Brunham RC
Infect Immun; 2010 May; 78(5):2272-82. PubMed ID: 20231405
[TBL] [Abstract][Full Text] [Related]
8. A peptide of Chlamydia trachomatis shown to be a primary T-cell epitope in vitro induces cell-mediated immunity in vivo.
Knight SC; Iqball S; Woods C; Stagg A; Ward ME; Tuffrey M
Immunology; 1995 May; 85(1):8-15. PubMed ID: 7543450
[TBL] [Abstract][Full Text] [Related]
9. Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin.
Cheng C; Bettahi I; Cruz-Fisher MI; Pal S; Jain P; Jia Z; Holmgren J; Harandi AM; de la Maza LM
Vaccine; 2009 Oct; 27(44):6239-46. PubMed ID: 19686693
[TBL] [Abstract][Full Text] [Related]
10. T cell responses to Chlamydia trachomatis.
Loomis WP; Starnbach MN
Curr Opin Microbiol; 2002 Feb; 5(1):87-91. PubMed ID: 11834375
[TBL] [Abstract][Full Text] [Related]
11. Towards a Chlamydia trachomatis vaccine: how close are we?
Cochrane M; Armitage CW; O'Meara CP; Beagley KW
Future Microbiol; 2010 Dec; 5(12):1833-56. PubMed ID: 21155665
[TBL] [Abstract][Full Text] [Related]
12. A live and inactivated Chlamydia trachomatis mouse pneumonitis strain induces the maturation of dendritic cells that are phenotypically and immunologically distinct.
Rey-Ladino J; Koochesfahani KM; Zaharik ML; Shen C; Brunham RC
Infect Immun; 2005 Mar; 73(3):1568-77. PubMed ID: 15731055
[TBL] [Abstract][Full Text] [Related]
13. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.
Sun G; Pal S; Weiland J; Peterson EM; de la Maza LM
Vaccine; 2009 Aug; 27(36):5020-5. PubMed ID: 19446590
[TBL] [Abstract][Full Text] [Related]
14. Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen.
Hadad R; Marks E; Kalbina I; Schön K; Unemo M; Lycke N; Strid Å; Andersson S
APMIS; 2016 Dec; 124(12):1078-1086. PubMed ID: 27859689
[TBL] [Abstract][Full Text] [Related]
15. [Development of vaccine preparation for urogenital Chlamydiosis prophylaxis].
Koroleva EA; Zigangirova NA
Zh Mikrobiol Epidemiol Immunobiol; 2011; (6):114-23. PubMed ID: 22308743
[TBL] [Abstract][Full Text] [Related]
16. Characterization of protective immune responses promoted by human antigen targets in a urogenital Chlamydia trachomatis mouse model.
Olsen AW; Andersen P; Follmann F
Vaccine; 2014 Feb; 32(6):685-92. PubMed ID: 24365515
[TBL] [Abstract][Full Text] [Related]
17. Chlamydia vaccine candidates and tools for chlamydial antigen discovery.
Rockey DD; Wang J; Lei L; Zhong G
Expert Rev Vaccines; 2009 Oct; 8(10):1365-77. PubMed ID: 19803759
[TBL] [Abstract][Full Text] [Related]
18. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.
Brown TH; David J; Acosta-Ramirez E; Moore JM; Lee S; Zhong G; Hancock RE; Xing Z; Halperin SA; Wang J
Vaccine; 2012 Jan; 30(2):350-60. PubMed ID: 22075089
[TBL] [Abstract][Full Text] [Related]
19. A genome-wide profiling of the humoral immune response to Chlamydia trachomatis infection reveals vaccine candidate antigens expressed in humans.
Wang J; Zhang Y; Lu C; Lei L; Yu P; Zhong G
J Immunol; 2010 Aug; 185(3):1670-80. PubMed ID: 20581152
[TBL] [Abstract][Full Text] [Related]
20. Chlamydial genomics and vaccine antigen discovery.
Stephens RS
J Infect Dis; 2000 Jun; 181 Suppl 3():S521-3. PubMed ID: 10839752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
